PCOS Is Now PMOS: Why the Name Change Matters for Patients and Diagnosis
For decades, polycystic ovary syndrome (PCOS) has been one of the most common but most misunderstood and underdiagnosed hormonal conditions affecting women. This spring, global medical experts announced an important change: PCOS has been officially renamed polyendocrine metabolic ovarian syndrome (PMOS).
While it may sound like a small shift in terminology, this new name represents a major step forward in how the condition is understood, diagnosed, and treated.
Why PCOS Needed a New Name
The term polycystic ovary syndrome has long been misleading. Despite the name, most people with the condition do not actually have ovarian cysts, and cysts are not required for diagnosis.
Focusing on “cysts” and “ovaries” led many patients and even clinicians to believe this was a purely gynecologic issue. The condition affects multiple systems throughout the body, including:
Hormone regulation
Metabolic health and insulin resistance
Weight regulation
Skin and hair
Mental health
Fertility and menstrual cycles
Experts say the old name contributed to delayed diagnosis, fragmented care, and stigma, with research suggesting that up to 70% of affected individuals go undiagnosed.
What PMOS Stands for and What It Reflects
The new name, polyendocrine metabolic ovarian syndrome (PMOS), was developed after 14 years of global collaboration involving clinicians, researchers, and patients from more than 50 organizations worldwide.
Each word in PMOS was chosen deliberately:
Polyendocrine acknowledges that multiple hormones—not just ovarian hormones—are involved
Metabolic highlights links to insulin resistance, diabetes risk, cholesterol, and heart health
Ovarian maintains recognition of reproductive effects without overstating cysts
Together, the new name better reflects what experts now know: PMOS is a chronic, whole‑body endocrine condition, not an isolated ovarian disorder.
What This Means for Diagnosing Patients
Importantly, the diagnostic criteria have not changed—but how clinicians think about and approach diagnosis is expected to improve.
Current international guidelines still diagnose PMOS when a patient meets two of the following three criteria (after excluding other conditions):
Irregular or absent ovulation
Elevated androgen levels (or symptoms such as acne or excess hair growth)
Polycystic ovaries on ultrasound or elevated anti‑Müllerian hormone (AMH)
For adolescents, only the first two criteria are used to avoid overdiagnosis.
However, by removing “polycystic” from the name, clinicians are less likely to rule out the diagnosis simply because an ultrasound looks normal. Experts believe this shift will lead to:
Earlier recognition, especially in teens and young adults
More comprehensive metabolic screening
Reduced reliance on imaging alone
Greater awareness of long‑term health risks, including diabetes and cardiovascular disease
Why This Matters for Patients
For patients, the PMOS name change offers more than medical accuracy—it offers validation.
Many people with PCOS have long struggled to explain symptoms that didn’t match the name of their diagnosis. Others were told they “couldn’t have PCOS” because they didn’t have cysts, despite experiencing irregular periods, excess hair growth, or metabolic issues.
By clearly defining PMOS as a multisystem condition, experts hope patients will:
Be taken seriously sooner
Receive more coordinated, whole‑person care
Better understand their symptoms and risks
Feel less stigma or confusion around the diagnosis
What Happens Next?
The transition from PCOS to PMOS will occur over a global, multi‑year rollout, with updates to clinical guidelines, medical records, educational materials, and disease classification systems already underway.
During this period, patients may hear both terms used together, such as “PMOS (formerly known as PCOS).” Experts emphasize that anyone previously diagnosed with PCOS still has the same condition—just a more accurate name.
Renaming PCOS to PMOS is more than a rebrand. It’s a recognition that this common condition is complex, systemic, and deserving of early, comprehensive care. By shifting the focus from ovarian cysts to hormonal and metabolic health, PMOS opens the door to better diagnosis, better treatment, and better outcomes for patients.
If you think you may have PMOS, talk to your doctor. Click here to find an OB/GYN near you.
